

AMENDMENT  
US APPLN. NO. 10/647,156


**Amendments to the Claims:**

**Listing of Claims as amended:**

**Claims:**

**1-44** (Cancelled)

**45. (New) Carboxamide compounds comprised of general formula I.1**



wherein

U, V independently of one another denote CH or N,

R<sup>23</sup>, R<sup>24</sup> independently of one another denote H, F or methyl,


R<sup>25</sup>, R<sup>26</sup>, R<sup>27</sup> independently of one another have one of the meanings given for R<sup>20</sup>  
or in the case of a phenyl group also simply denote nitro, while residues  
R<sup>25</sup>, R<sup>26</sup>, R<sup>27</sup> occurring several times may have identical or different  
meanings, and

j is 0, 1, 2, 3 or 4 and






m, n independently of one another represent 0, 1 or 2.

AMENDMENT  
US APPLN. NO. 10/647,156

$R^1, R^2$  independently of one another denote H, a  $C_{1-8}$ -alkyl or  $C_{3-7}$ -cycloalkyl group optionally substituted by the group  $R^{11}$  or a phenyl group optionally mono- or polysubstituted by the group  $R^{12}$  and/or monosubstituted by nitro, or



is defined according to one of the following partial formulae



wherein one or more H atoms of the heterocycle formed by the group  $R^1R^2N-$  may be replaced by  $R^{14}$  and the ring connected to the heterocycle

AMENDMENT  
US APPLN. NO. 10/647,156

formed by the group  $R^1R^2N-$  may be mono- or polysubstituted at one or more C atoms by  $R^{20}$ , and in the case of a phenyl ring may also additionally be monosubstituted by nitro;

$R^3$  denotes H, methyl or ethyl,

X denotes a single bond or a  $C_{1-8}$ -alkylene bridge wherein

one or two C atoms independently of one another may be substituted by a hydroxy,  $\omega$ -hydroxy- $C_{1-3}$ -alkyl-,  $\omega$ -( $C_{1-3}$ -alkoxy)- $C_{1-3}$ -alkyl- and/or  $C_{1-3}$ -alkoxy group and/or in each case with one or two identical or different  $C_{1-6}$ -alkyl groups, and/or

Cy denotes a carbo- or heterocyclic group selected from one of the following meanings

- a saturated 3- to 7-membered carbocyclic group,
- an unsaturated 5- to 7-membered carbocyclic group,
- a phenyl group,
- a saturated 4- to 7-membered or unsaturated 5- to 7-membered heterocyclic group with an N, O or S atom as heteroatom,
- a saturated or unsaturated 5- to 7-membered heterocyclic group with two or more N atoms or with one or two N atoms and an O or S atom as heteroatoms,
- an aromatic heterocyclic 5- or 6-membered group with one or more identical or different heteroatoms selected from N, O and/or S,

while the above mentioned 4, 5, 6 or 7-membered groups may be connected via two common, adjacent C atoms, fused with a phenyl or pyridine ring, and

AMENDMENT  
US APPLN. NO. 10/647,156

in the above mentioned 5-, 6- or 7-membered groups one or two non-adjacent -CH<sub>2</sub>-groups may be replaced by a -CO-, -C(=CH<sub>2</sub>)-, -(SO)- or -(SO<sub>2</sub>)-group, and

the above mentioned saturated 6- or 7-membered groups may also be present as bridged ring systems with an imino, N-(C<sub>1-4</sub>-alkyl)-imino, methylene, C<sub>1-4</sub>-alkyl-methylene or di-(C<sub>1-4</sub>-alkyl)-methylene bridge, and

the above mentioned cyclic groups may be mono- or polysubstituted at one or more C atoms with R<sup>20</sup>, and in the case of a phenyl group also additionally monosubstituted by nitro, and/or substituted by R<sup>21</sup> at one or more N atoms,

R<sup>11</sup> denotes R<sup>15</sup>-O-, R<sup>15</sup>-O-CO-, R<sup>16</sup>R<sup>17</sup>N-, R<sup>18</sup>R<sup>19</sup>N-CO- or Cy-,

R<sup>12</sup> has one of the meanings given for R<sup>20</sup>,

R<sup>14</sup> denotes halogen, C<sub>1-6</sub>-alkyl, R<sup>15</sup>-O-, R<sup>15</sup>-O-CO-, R<sup>16</sup>R<sup>17</sup>N-, R<sup>18</sup>R<sup>19</sup>N-CO-, R<sup>15</sup>-O-C<sub>1-3</sub>-alkyl-, R<sup>15</sup>-O-CO-C<sub>1-3</sub>-alkyl-, R<sup>16</sup>R<sup>17</sup>N-C<sub>1-3</sub>-alkyl-, R<sup>18</sup>R<sup>19</sup>N-CO-C<sub>1-3</sub>-alkyl- or Cy-C<sub>1-3</sub>-alkyl-,

R<sup>15</sup> denotes H, C<sub>1-4</sub>-alkyl, C<sub>3-7</sub>-cycloalkyl, C<sub>3-7</sub>-cycloalkyl-C<sub>1-3</sub>-alkyl-, phenyl, phenyl-C<sub>1-3</sub>-alkyl- or pyridinyl,

R<sup>16</sup> denotes H, C<sub>1-6</sub>-alkyl, C<sub>3-7</sub>-cycloalkyl, C<sub>3-7</sub>-cycloalkyl-C<sub>1-3</sub>-alkyl-, C<sub>4-7</sub>-cycloalkenyl, C<sub>4-7</sub>-cycloalkenyl-C<sub>1-3</sub>-alkyl-, ω-hydroxy-C<sub>2-3</sub>-alkyl-, ω-(C<sub>1-3</sub>-alkoxy)-C<sub>2-3</sub>-alkyl-, amino-C<sub>1-6</sub>-alkyl-, C<sub>1-3</sub>-alkyl-amino-C<sub>1-6</sub>-alkyl- or

AMENDMENT  
US APPLN. NO. 10/647,156

di-(C<sub>1-3</sub>-alkyl)-amino-C<sub>1-6</sub>-alkyl-,

- R<sup>17</sup> has one of the meanings given for R<sup>16</sup> or denotes phenyl, phenyl-C<sub>1-3</sub>-alkyl-, pyridinyl, dioxolan-2-yl, C<sub>1-3</sub>-alkylcarbonyl, hydroxycarbonyl-C<sub>1-3</sub>-alkyl-, C<sub>1-4</sub>-alkoxycarbonyl, C<sub>1-3</sub>-alkylcarbonylamino-C<sub>2-3</sub>-alkyl-, C<sub>1-3</sub>-alkylsulphonyl- or C<sub>1-3</sub>-alkylsulphonylamino-C<sub>2-3</sub>-alkyl-,
- R<sup>18</sup>, R<sup>19</sup> independently of one another denote H or C<sub>1-6</sub>-alkyl,
- R<sup>20</sup> denotes halogen, hydroxy, cyano, C<sub>1-4</sub>-alkyl, C<sub>3-7</sub>-cycloalkyl, hydroxy-C<sub>1-3</sub>-alkyl, R<sup>22</sup>-C<sub>1-3</sub>-alkyl- or has one of the meanings given for R<sup>22</sup>,
- R<sup>21</sup> denotes C<sub>1-3</sub>-alkyl, ω-hydroxy-C<sub>2-3</sub>-alkyl-, phenyl, phenyl-C<sub>1-3</sub>-alkyl-, C<sub>1-3</sub>-alkyl-carbonyl, carboxy, C<sub>1-4</sub>-alkoxy-carbonyl, C<sub>1-3</sub>-alkylsulphonyl, phenylcarbonyl or phenyl-C<sub>1-3</sub>-alkyl-carbonyl,
- R<sup>22</sup> denotes pyridinyl, phenyl, phenyl-C<sub>1-3</sub>-alkoxy-, C<sub>1-3</sub>-alkoxy, C<sub>1-3</sub>-alkylthio, carboxy, H-CO-, C<sub>1-3</sub>-alkylcarbonyl, C<sub>1-4</sub>-alkoxycarbonyl, aminocarbonyl, C<sub>1-3</sub>-alkylaminocarbonyl, di-(C<sub>1-3</sub>-alkyl)-aminocarbonyl, C<sub>1-3</sub>-alkyl-sulphonyl-, C<sub>1-3</sub>-alkyl-sulphanyl-, C<sub>1-3</sub>-alkyl-sulphonylamino-, amino, C<sub>1-3</sub>-alkylamino-, di-(C<sub>1-3</sub>-alkyl)-amino-, phenyl-C<sub>1-3</sub>-alkylamino- or N-(C<sub>1-3</sub>-alkyl)-phenyl-C<sub>1-3</sub>-alkylamino-, acetylamino-, propionylamino-, phenylcarbonyl, phenylcarbonylamino-, phenylcarbonylmethylamino-, hydroxyalkylaminocarbonyl, (4-morpholinyl)carbonyl, (1-pyrrolidinyl)-carbonyl, (1-piperidinyl)carbonyl, (hexahydro-1-azepinyl)carbonyl, (4-methyl-1-piperazinyl)carbonyl, methylenedioxy-, aminocarbonylamino- or alkylaminocarbonylamino-,

AMENDMENT  
US APPLN. NO. 10/647,156

while in the groups and residues X, R<sup>1</sup> to R<sup>3</sup> and R<sup>11</sup>, R<sup>12</sup> and R<sup>14</sup> to R<sup>22</sup> in each case one or more C atoms may be mono- or polysubstituted by F and/or in each case one or two C atoms independently of one another may be monosubstituted by Cl or Br, and/or in each case one or more phenyl rings independently of one another additionally have one, two or three substituents selected from the group F, Cl, Br, I, C<sub>1-4</sub>-alkyl, C<sub>1-4</sub>-alkoxy, difluoromethyl, trifluoromethyl, hydroxy, amino, C<sub>1-3</sub>-alkylamino-, di-(C<sub>1-3</sub>-alkyl)-amino-, acetylamino-, aminocarbonyl, CN, difluoromethoxy, trifluoromethoxy, amino-C<sub>1-3</sub>-alkyl-, C<sub>1-3</sub>-alkylamino-C<sub>1-3</sub>-alkyl- and di-(C<sub>1-3</sub>-alkyl)-amino-C<sub>1-3</sub>-alkyl- and/or may be monosubstituted by nitro, and

the tautomers, diastereomers, enantiomers, mixtures thereof and the salts thereof.

46. (New) The carboxamide compounds according to claim 45, wherein R<sup>1</sup>, R<sup>2</sup> independently of one another denote H, C<sub>1-6</sub>-alkyl, C<sub>3-7</sub>-cycloalkyl, C<sub>3-7</sub>-cycloalkyl-C<sub>1-3</sub>-alkyl-, ω-hydroxy-C<sub>2-3</sub>-alkyl, ω-(C<sub>1-3</sub>-alkoxy)-C<sub>2-3</sub>-alkyl-, C<sub>1-4</sub>-alkoxy-carbonyl-C<sub>1-3</sub>-alkyl, amino-C<sub>2-4</sub>-alkyl-, C<sub>1-3</sub>-alkyl-amino-C<sub>2-4</sub>-alkyl- or di-(C<sub>1-3</sub>-alkyl)-amino-C<sub>2-4</sub>-alkyl-, phenyl or phenyl-C<sub>1-3</sub>-alkyl-,

while in the above mentioned groups and residues one or more C atoms may be mono- or polysubstituted by F and/or one or two C atoms independently of one another may be monosubstituted by Cl or Br and

the phenyl group may be mono- or polysubstituted by the group R<sup>12</sup> defined in claim 45 and/or monosubstituted by nitro.

47. (New) The carboxamide compounds according to claim 45, wherein R<sup>1</sup>, R<sup>2</sup> independently of one another denote C<sub>1-4</sub>-alkyl, C<sub>3-7</sub>-cycloalkyl, C<sub>3-7</sub>-cycloalkyl-C<sub>1-3</sub>-alkyl-, ω-hydroxy-C<sub>2-3</sub>-alkyl-, ω-(C<sub>1-3</sub>-alkoxy)-C<sub>2-3</sub>-alkyl-, C<sub>1-4</sub>-

AMENDMENT  
US APPLN. NO. 10/647,156

alkoxy-carbonyl-C<sub>1-3</sub>-alkyl-, while one of the groups R<sup>1</sup>, R<sup>2</sup> may also denote H.

48. (New) The carboxamide compounds according to claim 45, wherein R<sup>1</sup>, R<sup>2</sup> form with the N atom of the group R<sup>1</sup>R<sup>2</sup>N- a pyrrolidine, piperidine or 2,5-dihydro-1H-pyrrole ring, wherein one or more H atoms may be replaced by R<sup>14</sup> and wherein R<sup>14</sup> is defined as in claim 45.

49. (New) The carboxamide compounds according to claim 45, wherein R<sup>14</sup> is selected from the group consisting of halogen, C<sub>1-4</sub>-alkyl, hydroxy, C<sub>1-4</sub>-alkoxy, C<sub>1-4</sub>-alkoxy-C<sub>1-3</sub>-alkyl-, hydroxy-C<sub>1-3</sub>-alkyl, C<sub>1-4</sub>-alkoxy-carbonyl, C<sub>1-4</sub>-alkoxy-carbonyl-C<sub>1-3</sub>-alkyl-, C<sub>1-4</sub>-alkoxy-carbonylamino-, C<sub>1-4</sub>-alkoxy-carbonylamino-C<sub>1-3</sub>-alkyl-, amino, (C<sub>1-4</sub>-alkyl)-amino-, di-(C<sub>1-4</sub>-alkyl)-amino-.

50. (New) The carboxamide compounds according to claim 45, wherein X denotes a single bond or an alkylene bridge selected from methylene, 1,2-ethylene, 1,3-propylene and 1,4-butylene,

wherein one or two C atoms independently of one another may be substituted with a hydroxy, ω-hydroxy-C<sub>1-3</sub>-alkyl, ω-(C<sub>1-3</sub>-alkoxy)-C<sub>1-3</sub>-alkyl- and/or C<sub>1-3</sub>-alkoxy group and/or in each case may be substituted with one or two identical or different C<sub>1-4</sub>-alkyl groups, and

in each case one or more C atoms may be mono- or polysubstituted by F and/or in each case one or two C atoms independently of one another may be monosubstituted by Cl or Br.

AMENDMENT  
US APPLN. NO. 10/647,156

51. (New) The carboxamide compounds according to claim 45, wherein X is -  
 $\text{CH}_2-$ ,  $-\text{CH}(\text{CH}_3)-$  or  $-\text{C}(\text{CH}_3)_2-$ .
52. (New) The carboxamide compounds according to claim 45, wherein  $\text{R}^3$  is H  
or methyl.
53. (New) The carboxamide compounds according to claim 45, wherein the  
group U denotes an N atom and the group V denotes a C atom.
54. (New) The carboxamide compounds according to claim 45, wherein the  
group U denotes a C atom and the group V denotes a N atom.
55. (New) The carboxamide compounds according to claim 45, wherein the two  
groups U and V each denote a C atom.
56. (New) Carboxamide compounds according to claim 45, wherein  
 $\text{R}^{25}$ ,  
 $\text{R}^{26}, \text{R}^{27}$  independently of one another denote F, Cl, Br, I, OH, cyano,  
methyl, difluoromethyl, trifluoromethyl, ethyl, n-propyl, iso-propyl,  
methoxy, difluoromethoxy, trifluoromethoxy, ethoxy, n-propoxy or  
iso-propoxy, in the case of a substitution of a phenyl group they  
may also denote nitro, while repeatedly occurring groups  $\text{R}^{25}, \text{R}^{26},$   
 $\text{R}^{27}$  may have identical or different meanings, and

j is 0, 1 or 2, and

m, n independently of one another are 0 or 1.

57. (New) The carboxamide compounds according to claim 45, wherein the  
group  $\text{R}^{11}$  is selected from  $\text{C}_{1-6}$ -cycloalkyl, hydroxy,  $\text{C}_{1-4}$ -alkoxy, amino,  $\text{C}_{1-4}$ -

AMENDMENT  
US APPLN. NO. 10/647,156

alkyl-amino- and di-(C<sub>1-4</sub>-alkyl)-amino-.

58. (New) The carboxamide compounds according to claim 45, wherein the group R<sup>20</sup> is selected from halogen, hydroxy, cyano, C<sub>1-4</sub>-alkyl, C<sub>3-7</sub>-cycloalkyl and hydroxy-C<sub>1-3</sub>-alkyl.
59. (New) The carboxamide compounds according to claim 45, wherein the group R<sup>20</sup> is selected from among fluorine, chlorine, bromine, CF<sub>3</sub>, C<sub>1-4</sub>-alkyl and C<sub>1-4</sub>-alkoxy.
60. (New) Carboxamide compounds according to claim 45 selected from among the formulae:
  - (1) 4'-chloro-biphenyl-4-carboxylic acid [2-(4-pyrrolidin-1-ylmethyl-phenyl)-ethyl]-amide
  - (2) 4'-chloro-biphenyl-4-carboxylic acid-[2-(4-diethylaminomethyl-phenyl)-ethyl]-amide
  - (3) 4'-chloro-biphenyl-4-carboxylic acid-[2-(4-piperidin-1-ylmethyl-phenyl)-ethyl]-amide
  - (4) 4'-methoxy-biphenyl-4-carboxylic acid-[2-(4-diethylaminomethyl-phenyl)-ethyl]-amide
  - (5) 4'-chloro-biphenyl-4-carboxylic acid-[2-(4-diethylaminomethyl-phenyl)-ethyl]-methyl-amide
  - (6) 4'-chloro-biphenyl-4-carboxylic acid-[2-(4-pyrrolidin-1-ylmethyl-phenyl)-propyl]-amide
  - (7) 4'-chloro-biphenyl-4-carboxylic acid-[2-(3-methoxy-4-pyrrolidin-1-ylmethyl-phenyl)-ethyl]-amide

AMENDMENT  
US APPLN. NO. 10/647,156

- (8) 4'-chloro-biphenyl-4-carboxylic acid-{2-[6-(4-methyl-piperazin-1-yl)-pyridin-3-yl]-ethyl}-amide
- (9) 4'-chloro-biphenyl-4-carboxylic acid-[2-methyl-2-(4-pyrrolidin-1-ylmethyl-phenyl)-propyl]-amide
- (10) 4-benzyl-N-[2-(4-pyrrolidin-1-ylmethyl-phenyl)-ethyl]-benzamide
- (11) 4'-chloro-biphenyl-4-carboxylic acid-[2-(2-fluoro-4-pyrrolidin-1-ylmethyl-phenyl)-ethyl]-amide
- (12) 4'-chloro-biphenyl-4-carboxylic acid [2-(3-bromo-4-pyrrolidin-1-ylmethyl-phenyl)-ethyl]-amide
- (13) 4'-chloro-biphenyl-4-carboxylic acid [2-(3-methyl-4-pyrrolidin-1-ylmethyl-phenyl)-ethyl]-amide
- (14) 4'-chloro-biphenyl-4-carboxylic acid {2-[4-(1-ethyl-piperidin-2-yl)-phenyl]-ethyl}-amide
- (15) 4'-chloro-biphenyl-4-carboxylic acid{2-[4-(4-acetyl-piperazin-1-ylmethyl)-phenyl]-ethyl}-amide
- (16) 4'-chloro-biphenyl-4-carboxylic acid (2-{4-[(diisopropylamino)-methyl]-phenyl}-ethyl)-amide
- (17) 4'-chloro-biphenyl-4-carboxylic acid {2-[3-bromo-4-(2,5-dihydro-pyrrol-1-ylmethyl)-phenyl]-ethyl}-amide
- (18) 4'-chloro-biphenyl-4-carboxylic acid{2-[4-(2-dimethylaminomethyl-pyrrolidin-1-ylmethyl)-phenyl]-ethyl}-amide
- (19) 4'-chloro-biphenyl-4-carboxylic acid{2-[4-(3-dimethylamino-pyrrolidin-1-ylmethyl)-phenyl]-ethyl}-amide
- (20) 4'-chloro-biphenyl-4-carboxylic acid [2-(2-bromo-4-pyrrolidin-1-ylmethyl-phenyl)-ethyl]-amide
- (21) 4'-chloro-biphenyl-4-carboxylic acid [2-(6-pyrrolidin-1-ylmethyl-pyridin-3-yl)-ethyl]-amide

AMENDMENT  
US APPLN. NO. 10/647,156

- (22) 4'-chloro-biphenyl-4-carboxylic acid [2-(2-nitro-4-pyrrolidin-1-ylmethyl-phenyl)-ethyl]-amide
- (23) 2',4'-dichloro-biphenyl-4-carboxylic acid [2-(4-pyrrolidin-1-ylmethyl-phenyl)-ethyl]-amide
- (24) 4'-chloro-biphenyl-4-carboxylic acid{2-[4-(3-amino-pyrrolidin-1-ylmethyl)-phenyl]-ethyl}-amide
- (25) 4'-chloro-biphenyl-4-carboxylic acid{2-[4-(2-aminomethyl-pyrrolidin-1-ylmethyl)-phenyl]-ethyl}-amide
- (26) 4'-chloro-biphenyl-4-carboxylic acid [2-(5-pyrrolidin-1-ylmethyl-pyridin-2-yl)-ethyl]-amide
- (27) 4'-chloro-biphenyl-4-carboxylic acid [2-(3-ethyl-4-pyrrolidin-1-ylmethyl-phenyl)-ethyl]-amide
- (28) 4'-bromo-biphenyl-4-carboxylic acid {2-[4-(2,5-dihydro-pyrrol-1-ylmethyl)-phenyl]-ethyl}-amide
- (29) 4'-chloro-biphenyl-4-carboxylic acid [2-(2-methyl-4-pyrrolidin-1-ylmethyl-phenyl)-ethyl]-amide
- (30) 4'-bromo-3-fluoro-biphenyl-4-carboxylic acid {2-[3-bromo-4-(2,5-dihydro-pyrrol-1-ylmethyl)-phenyl]-ethyl}-amide
- (31) 4'-chloro-2-fluoro-biphenyl-4-carboxylic acid [2-(4-pyrrolidin-1-ylmethyl-phenyl)-ethyl]-amide
- (32) 4'-ethyl-biphenyl-4-carboxylic acid [2-(4-pyrrolidin-1-ylmethyl-phenyl)-ethyl]-amide
- (33) 4'-chloro-biphenyl-4-carboxylic acid {2-[4-(2-methyl-piperidin-1-ylmethyl)-phenyl]-ethyl}-amide
- (34) 4'-chloro-biphenyl-4-carboxylic acid {2-[4-(2-methyl-pyrrolidin-1-ylmethyl)-phenyl]-ethyl}-amide
- (35) 4'-chloro-biphenyl-4-carboxylic acid (2-{4-[(cyclopropylmethyl-amino)-

AMENDMENT  
US APPLN. NO. 10/647,156

methyl]-phenyl}-ethyl)-amide

- (36) 4'-chloro-biphenyl-4-carboxylic acid {2-[4-(3,4-dihydro-1H-isoquinolin-2-ylmethyl)-phenyl]-ethyl}-amide
- (37) 4'-chloro-biphenyl-4-carboxylic acid [2-(4-{[(2-hydroxy-ethyl)-methyl-amino]-methyl}-phenyl)-ethyl]-amide
- (38) 4'-chloro-biphenyl-4-carboxylic acid {2-[4-(2,6-dimethyl-piperidin-1-ylmethyl)-phenyl]-ethyl}-amide
- (39) 4'-chloro-biphenyl-4-carboxylic acid [2-(4-azetidin-1-ylmethyl-phenyl)-ethyl]-amide
- (40) 3,4'-dichloro-biphenyl-4-carboxylic acid [2-(4-pyrrolidin-1-ylmethyl-phenyl)-ethyl]-amide
- (41) 4'-fluoro-biphenyl-4-carboxylic acid [2-(4-pyrrolidin-1-ylmethyl-phenyl)-ethyl]-amide
- (42) 4'-chloro-3-fluoro-biphenyl-4-carboxylic acid [2-(4-pyrrolidin-1-ylmethyl-phenyl)-ethyl]-amide
- (43) 2'-fluoro-4'-chloro-biphenyl-4-carboxylic acid [2-(4-pyrrolidin-1-ylmethyl-phenyl)-ethyl]-amide
- (44) 5-(4-chloro-phenyl)-pyridine-2-carboxylic acid [2-(4-pyrrolidin-1-ylmethyl-phenyl)-ethyl]-amide
- (45) 4'-chloro-biphenyl-4-carboxylic acid {2-[4-(2,5-dihydro-pyrrol-1-ylmethyl)-phenyl]-ethyl}-amide
- (46) 4'-bromo-biphenyl-4-carboxylic acid [2-(4-pyrrolidin-1-ylmethyl-phenyl)-ethyl]-amide
- (47) 4'-chloro-biphenyl-4-carboxylic acid {2-[4-(1-pyrrolidin-1-yl-ethyl)-phenyl]-ethyl}-amide

and the pharmaceutically acceptable salts thereof.

AMENDMENT  
US APPLN. NO. 10/647,156

61.(New) The physiologically acceptable salts of the carboxamide compounds according to claim 45.

62.(New) Method of influencing the eating behavior of a mammal comprised of administering to a mammal a pharmaceutically effective amount of a carboxamide compound according to claim 45.

63.(New) A composition comprised of at least one carboxamide compound according to claim 45 further comprised of one or more physiologically acceptable excipients.

64.(New) A pharmaceutical composition, comprising at least one carboxamide compound according to claim 45 optionally together with one or more inert carriers and/or diluents.

65.(New) Method of influencing the eating behaviour of a mammal comprised of administering to a mammal a therapeutically effective amount of a compound according to claim 45 or a pharmaceutically acceptable salt thereof.

66. (New) A method of reducing the body weight and/or prevention of an increase of body weight of a mammal comprised of the administration of a therapeutically effective amount of a carboxamide compound according to claim 45 to a mammal or a pharmaceutically acceptable salt thereof.

67.(New) Use of at least one carboxamide compound according to claim 45 for preparing a pharmaceutical composition with an MCH-receptor-antagonistic activity.

AMENDMENT  
US APPLN. NO. 10/647,156

- 68.(New) Method of preventing and/or treating symptoms and/or diseases which are caused by MCH or otherwise casually connected with MCH, comprised of the administration to a patient in need thereof a pharmaceutically effective amount of a compound according to claim 45 or a pharmaceutically acceptable salt thereof.
- 69.(New) A method of treating metabolic disorders and/or eating disorders, obesity, bulimia, bulimia nervosa, cachexia, anorexia nervosa and hyperphagia comprised of the administration to a patient in need thereof of a pharmaceutically effective amount of a carboxamide compound according to claim 45 or a pharmaceutically acceptable salt thereof.
- 70.(New) Method of preventing and/or treating diseases and/or disorders associated with obesity, particularly diabetes, especially type II diabetes, complications of diabetes including diabetic retinopathy, diabetic neuropathy, diabetic nephropathy, insulin resistance, pathological glucose tolerance, encephalorrhagia, cardiac insufficiency, cardiovascular diseases, particularly arteriosclerosis and high blood pressure, arthritis and gonitis comprised of administering to a patient in need thereof a therapeutically effective amount of a compound according to claim 45 or a pharmaceutically acceptable salt thereof.
- 71.(New) Method of preventing or treating hyperlipidaemia, cellulitis, fat accumulation, malignant mastocytosis, systemic mastocytosis, emotional disorders, affective disorders, depression, anxiety, sleep disorders, reproductive disorders, sexual disorders, memory disorders, epilepsy, forms of dementia and hormonal disorders comprised of administering to a patient in need thereof therapeutically effective amount of a carboxamide compound according to claim 45 or a pharmaceutically acceptable salt thereof.

AMENDMENT  
US APPLN. NO. 10/647,156

72. (New) A method of preventing and/or treating micturition disorders, selected from a list consisting of urinary incontinence, hyperactive urinary bladder, urgency, nycturia and enuresis comprised of administering to a patient in need thereof a therapeutically effective amount of a compound according to claim 45 or a pharmaceutically acceptable salt thereof.
73. (New) Pharmaceutical compositions, comprised of a first active substance selected from the carboxamide compounds according to claim 1 and a second active substance selected from the group comprised of active substances for the treatment of diabetes, active substances for the treatment of diabetic complications, active substances for the treatment of obesity, other than MCH antagonists, active substances for the treatment of high blood pressure, active substances for the treatment of hyperlipidaemia, including arteriosclerosis, active substances for the treatment of arthritis, active substances for the treatment of anxiety states and active substances for the treatment of depression, optionally together with one or more inert carriers and/or diluents.